- XTL Biopharmaceuticals (NASDAQ:XTLB) Q2 results: Revenues: $0; R&D Expense: $0.07M (+133.3%); SG&A: $0.4M (+10.8%); Operating Loss: ($0.5M) (-25.0%); Net Loss: ($0.4M) (-13.2%); Loss Per Share: $0.00; Quick Assets: $4.8M (+77.8%).
- No guidance given.
XTL Biopharma reports Q2 results
Recommended For You
More Trending News
About XTLB Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| XTLB | - | - |
| XTL Biopharmaceuticals Ltd. | ||